ATCC Licensing Program Aids Genmab Drug Development
News Jan 09, 2006
The worldwide, non-exclusive Genmab agreement is the latest in a series of commercial licensing arrangements that enable characterized ATCC biological materials to be used for a variety of industrial R&D purposes.
The ATCC-Genmab agreement will allow the biotech firm to employ an ATCC cell line standard in testing the potency of manufacturing batches of human monoclonal antibodies that the company is developing.
The assays will be used with Genmab antibodies designed to recognize specific cell surface receptors.
"ATCC is delighted to have the chance to provide our biomaterials to Genmab as they navigate the final stages of drug development," said ATCC VP for Licensing, Contracts and Compliance Jesus Soriano, MD/PhD.
"Arrangements such as the one between ATCC and Genmab reflect ATCC's willingness to address the increasing demand for commercial use of ATCC biological standards."
ATCC's non-exclusive licensing program ensures equitable access to reference research materials that are otherwise available under the ATCC Material Transfer Agreement, a contract that limits the use of ATCC biomaterials to non-commercial scientific research.
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE